Tianshili announced that the company received the “Drug Clinical Trial Approval Notice” for TDX105 granules approved and issued by the State Drug Administration. TDX105 granules are an innovative traditional Chinese medicine class 1.1, and it was agreed to carry out phase II and III clinical trials to block moisture, heat, and stasis associated with adverse skin reactions caused by chemotherapy and targeted treatment of tumors. As of the announcement date, the company has invested a total of 126.267 million yuan in research and development of this drug. The drug will need to complete clinical trials and review before it can be marketed. There is uncertainty.

Zhitongcaijing · 2d ago
Tianshili announced that the company received the “Drug Clinical Trial Approval Notice” for TDX105 granules approved and issued by the State Drug Administration. TDX105 granules are an innovative traditional Chinese medicine class 1.1, and it was agreed to carry out phase II and III clinical trials to block moisture, heat, and stasis associated with adverse skin reactions caused by chemotherapy and targeted treatment of tumors. As of the announcement date, the company has invested a total of 126.267 million yuan in research and development of this drug. The drug will need to complete clinical trials and review before it can be marketed. There is uncertainty.